Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are more likely to have recurring symptoms. Using a novel "clotting chamber" the investigators have shown that patients with diabetes are more likely to develop blood clots. This study will look at the role of different blood thinning medications in patients with diabetes. If successful, the investigators will provide evidence to conduct large clinical studies to look at the role of additional blood thinning medication in reducing heart attacks and strokes in patients with diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
• Collaborators: British Heart Foundation; University of Newcastle Upon-Tyne
• Treatments: Aspirin; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Patients with T2DM and CAS as defined below:

• Clinical definitions

• T2DM: Diagnosed according to the WHO criteria [53].

• CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.

• Aged between 18 and 75

• Provided written consent for participation in the trial prior to any study-specific procedures or requirements.

Exclusion Criteria:

• Contraindication to Clopidogrel

• Smoking (current smokers and patients who quit smoking less than six months)

• Malignancy(diagnosed or under investigation)

• Haematological disorders (Anaemia, malignancy, bleeding disorders)

• Women of child-bearing potential

• Use of corticosteroids/other antithrombotic agents(warfarin)

• Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests)

• Unable to consent.

• Use of other investigational study drugs within 1 year prior to study entry

• Previous participation in this study